CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02371187
NCT02371187Phase 2Completed

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Christopher Bell·interventional·Posted Feb 25, 2015·Updated Apr 10, 2019

In Brief

A Phase 2 clinical trial evaluating Dapagliflozin and Placebo for Physical Activity. Completed, enrolled 37 participants across 1 site.

Detailed Summary

Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAstraZeneca

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 25, 2015
Enrollment StartJun 1, 2015
Primary CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.4 years ago

Interventions

Dapagliflozindrug

Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.

Placebodrug

Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.